Saterinone, a phosphodiesterase (PDE) III inhibitor and α1-adrenergic antagonist

Cardiovascular Drug Reviews

Volumn 17, Issue 4, 1999, Pages 374-383

  Kieback, A G ^a   Baumann, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cardiovascular drugs; Phosphodiesterase III inhibitors; Saterinone; 1 Adrenoceptor antagonists

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ACETYLSALICYLIC ACID; ADIBENDAN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIPYRIDINE DERIVATIVE; CALCIUM; CARBACHOL; DIHYDROOUABAIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; MILRINONE; NITROPRUSSIDE SODIUM; O NORPIMOBENDAN; PHENOXYBENZAMINE; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PRAZOSIN; SATERINONE; SULMAZOLE; URAPIDIL; VASODILATOR AGENT;

CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HEMODYNAMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033512175     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00026.x     Document Type: Review

References (23)

1. Armah BI, Hofferber E, Jacobilz P. Positive inotropic and vasodilatory actions of saterinone in vivo. Arzneimittelforschung 1988;38:1303-1309.
2. 1-adrenoceptor blocking agent saterinone. Arzneimittelforschung 1988;38:1287-1292.
3. Armah BI, Muster D, Raap A, Brückner R, Graziadei I. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers. Arzneimittelforschung 1989;39:1384-1392.
4. Baumann G, Kieback AG, Eichner E, Iven H, Stolzenburg K. Pharmacokinetics and pharmacodynamics of saterinone i.v. in patients with severe chronic heart failure. (Abstract). Eur Heart J 1992;13:SII-IV; and unpublished data.
5. Baumann G, Ningel K, Permanetter B. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1989;13:730-738.
6. 1-antagonist saterinone (INN) in healthy volunteers. Naunyn Schmiedeberg's Arch Pharmacol 1988; 338:R78. (Abstract 258).
7. Brunkhorst D, von der Leyen H, Meyer W, Schmidt-Schumacher C, Scholz H. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent salerinone in guinea pig myocardium. Arzneimittelforschung 1988;38:1293-1298.
8. Iven H, Brasch H, Armah BI. Electrophysiologic effects of saterinone and milrinone in the isolated guinea pig myocardium. Arzneimittelforschung 1988;38:1298-1302.
9. Iven H, Djonlagic H. Pharmacokinetics and pharmacodynamics of saterinone in 12 healthy volunteers after i.v. infusion and bioavailability from tablets. Naunyn Schmiedebergs Arch Pharmacol 1988;338:R77. (Abstract 257).
10. Kieback AG, Iven H, Stolzenburg K, Baumann G. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. J Cardiovasc Pharmacol 1998;32:629-636.
11. Kitamura K, Jorgensen CR, Gobel FL, Taylor HL, Wang Y. Hemodynamic correlates of myocardial oxygen consumption during upright exercise. J Appl Physiol 1972;32:516-522.
12. Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 1988;12:1299-1317.
13. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
14. Rudolph M. Determination of saterinone in plasma by high-performance liquid chromatography. J Chromatogr 1989;497:342-348.
15. Rudolph M. Direct enantiomeric separation of saterinone by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1990;525/1:161-168.
16. 14C]saterinone and its metabolism in dog plasma, urine, and bile by high-performance liquid chromatography with radioactivity and fluorescence detection and by mass spectrometry. J Pharm Biomed Anal 1992;10:295-302.
17. Rudolph M, Volk D, Schmiedel G. Determination of saterinone enantiomers in plasma samples with an internal standard using a Chiralcel OD column, fractionation, and reversed-phase chromatography. J Chromatogr 1990;535:263-269.
18. Szabo BM, van Veldhuisen DJ, van Dijk RB, et al. Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure. J Cardiovasc Pharmacol 1997;29:618-623.
19. 1 adenosine receptors and m-cholinoceptors in human myocardium. Naunyn Schmiedeberg's Arch Pharmacol 1990; 341:577-585.
20. van Zwieten PA. Pharmakologisches Profil von Urapidil. Fortschr Med 1992;17:330-332.
21. von der Leyen H, Mende U, Meyer W, et al. Mechanism underlying the reduced positive inotropic effects of the phosphociesterase III inhibitors pimobendan, adibendan, and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedeberg's Arch Pharmacol 1991;344:90-100.
22. Weber PW, Kupper W, Hamm CW, Heitmann NB, Bleifeld W. Acute hemodynamic effects of saterinone in patients with severe chronic heart failure. (Abstract). Eur Heart J 1990;11:SII-IV.
23. Werner K, Stolzenburg K, Vey G, Schoeller R. Saterinone i.v. in advanced congestive heart failure, a dose titration study. (Abstract). Cardiovasc Drugs Ther 1991;5(Suppl 3):213.